|
Exchange Received Time  30/11/2019 16:40:34 Exchange Disseminated Time 30/11/2019 16:40:39 Time Taken 00:00:05 | Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients with Moderate Alzheimer''s Disease (AD) |
|
|